Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 8, 2010, Pages 909-918

  Mallam, Elizabeth ^a   Kemp, Kevin ^a   Wilkins, Alastair ^a   Rice, Claire ^a   Scolding, Neil ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

differentiation; immunophenotype; mesenchymal stem cells; Multiple sclerosis; proliferation

Indexed keywords

MEMBRANE ANTIGEN; METHYLPREDNISOLONE;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEMUR HEAD; HUMAN; HUMAN CELL; ILIAC CREST; IMMUNOPHENOTYPING; MALE; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOPHENOTYPING; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; REFERENCE VALUES;

EID: 77955159550     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510371959     Document Type: Article

References (33)

1. Charcot JM Histologie de la sclerose en plaques. Gazette des Hopitaux, Paris 1868 ; 41: 554-555.
2. Li Y., Chen J., Chen XG, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002 ; 59: 514-523.
3. Cogle CR, Yachnis AT, Laywell ED, et al. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet 2004 ; 363: 1432-1437.
4. Weimann JM, Charlton CA, Brazelton TR, Hackman RC and Blau HM Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Proc Natl Acad Sci USA 2003 ; 100: 2088-2093.
5. Gordon D., Pavlovska G., Glover CP, Uney JB, Wraith D. and Scolding NJ Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett 2008 ; 448: 71-73.
6. Zhang J., Li Y., Chen J., et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005 ; 195: 16-26. (Pubitemid 41116810)
7. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005 ; 106: 1755-1761.
8. Bossolasco P., Cova L., Calzarossa C., et al. Neuro-glial differentiation of human bone marrow stem cells in vitro. Exp Neurol 2005 ; 193: 312-325.
9. Wislet-Gendebien S., Hans G., Leprince P., Rigo JM, Moonen G. and Rogister B. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 2005 ; 23: 392-402.
10. Parr AM, Tator CH and Keating A. Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant 2007 ; 40: 609-619.
11. Singec I. and Snyder EY Inflammation as a matchmaker: revisiting cell fusion. Nat Cell Biol 2008 ; 10: 503-505.
12. Uccelli A., Moretta L. and Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006 ; 36: 2566-2573. (Pubitemid 44608440)
13. Crigler L., Robey RC, Asawachaicharn A., Gaupp D. and Phinney DG Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006 ; 198: 54-64.
14. Wilkins A., Kemp K., Ginty M., Hares K., Mallam E. and Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009 ; 3: 63-70.
15. Rice CM, Mallam EA, Whone AL, et al. Study of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. lin Pharmacol Ther 2010 ; 87: 679-685.
16. Del Papa N., Quirici N., Soligo D., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006 ; 54: 2605-2615.
17. Papadaki HA, Boumpas DT, Gibson FM, et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 2001 ; 115: 167-174.
18. Papadaki HA, Kritikos HD, Gemetzi C., et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002 ; 99: 1610-1619.
19. Larghero J., Farge D., Braccini A., et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 2008 ; 67: 443-449.
20. Papadaki HA, Tsagournisakis M., Mastorodemos V., et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant 2005 ; 36: 1053-1063.
21. Bocelli-Tyndall C., Bracci L., Spagnoli G., et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneicstimulated lymphocytes in vitro. Rheumatology (Oxford) 2007 ; 46: 403-408.
22. Rice CM, Whone AL, Marks DI, Butler S., Brooks DJ and Scolding NJ A safety and feasibility study of intravenous autologous bone marrow stem cells in multiple sclerosis. J Neurol Neurosurg Psych 2007 ; 78: 1036.
23. Greenwood SK, Hill RB, Sun JT, et al. Population doubling: a simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results. Environ Mol Mutagen 2004 ; 43: 36-44.
24. Ferrero I., Mazzini L., Rustichelli D., et al. Bone marrow mesenchymal stem cells from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant 2008 ; 17: 255-266.
25. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006 ; 8: 315-317.
26. Urbani S., Caporale R., Lombardini L., Bosi A. and Saccardi R. Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. Cytotherapy 2006 ; 8: 243-253.
27. Mazzanti B., Aldinucci A., Biagioli T., et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol 2008 ; 199: 142-150.
28. Kastrinaki MC, Sidiropoulos P., Roche S., et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 2008 ; 67: 741-749.
29. Mareschi K., Ferrero I., Rustichelli D., et al. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem 2006 ; 97: 744-754.
30. Stenderup K., Justesen J., Clausen C. and Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003 ; 33: 919-926.
31. Li J., Law HK, Lau YL and Chan GC Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents. Br J Haematol 2004 ; 127: 326-334.
32. Lanza C., Morando S., Voci A., et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009 ; 110: 1674-1684.
33. Freedman MS, Bar-Or A., Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis 2010 ; 16: 503-510.